3Heddle N M, Cook R J, Sigouin C, et al. A descriptive analy- sis of international transfusion practice and bleeding outcomes in patients with acute leukemia [ J ]. Transfusion, 2006, 46 (6) : 903.
5Stanworth S J, Dyer C, Chc~, L, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions [J]. Transfus Med Rev. 2010, 24(3) : 163.
二级参考文献9
1Cameron B, Rock B, Olberg B, et al. Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion, 2007,47(2) :206-211.
2Greeno E, McCullough J, Weisdorf D. Platelet utilization and the transfusion trigger.- A prospective analysis. Transfusion, 2007, 47(2) :201-205.
3Heddle NM, Cook RJ, Tinmouth A, et al. A randomized controlled trial comparing standard and low-dose strategies for transfusion of platelets ( SToP ) to patients with thrombocytopenia. Blood, 2009,113 (7) : 1564-1573.
4Stanworth S3, Dyer C, Choo I., et al. Do all patients with hematologic malignancies and severe thrombocytnpenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platclet transfusions. Transfus Med Rev. 2010, 24(3) :163-171.
5Sherrill J. Slichter, Richard M. Kaufman, Susan F. Assmann, el al. Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage. N ENGLJ MEI), 2010, 362(7) :600-613.
6Tinmouth A, Tannock IF, Crump M, ct al. Lowdose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and palienls with acute leukemia: A randomized controlled trial with a sectuemial Bayesian design. Transfusion, 2004,44(12):1711-1719.
7Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Trans Med Rev, 2004,18( 3): 153 167.
8Schrezenmeier H, Seifried E. Buffy coat-derived pooled platelct concentrates and apheresis platelet concentrates: Which product type should be preferred? Vox Sang, 2010,99( 1 ) : 1 15.
9Heddle NM, Cook RJ, Sigouin C, et al. A descriptive analysis of international transfusion practice and bleeding outcnmes in patients with acute leukemia. Transfusion, 200(3,46((1):903-911.
2Zhi L, Chi X, Gelderman MP,et al. Activation of platelet protein ki- nase C by ultraviolet light B mediates platelet transfusion-related acute lung injury in a two-event animal model [ J ]. Transfusion ( Paris ) , 2013,53(4) :722-731.
3Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies : an open-label, muhicentre, randomiseds- tudy[J]. Lancet,2012,380(9850) :1309-1316.
4Nakastoev IM, Grachev AE, Geradzhian EG, et al. Clinical efficiency of transfusion of pathogen-inactivated platelet concentrates [ J ]. Terapevti- cheskii arkhiv ,2013,85 ( 8 ) :77-80.
